For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
News Release
Senate Parliamentarian Eliminates Medicaid Reform Provisions, Leaving Costs/Problems Intact
The Senate’s parliamentarian has determined that many of the Medicaid provisions in the One Big Beautiful Bill cannot be passed with simple majority vote via…
Blog
FDA can’t stomach fluoride and doesn’t want you to, either
On May 13, the Food and Drug Administration (FDA) announced that it would begin a process intended to exclude ingestible prescription fluoride products for…
Blog
Free the Economy podcast: Drug costs and benefits with Sally Pipes
In this week’s episode we cover reforms to the Endangered Species Act, attacks on US tech firms, nuclear power innovation,…
Search Posts
Fox News
DeSantis’s Florida beats Newsom’s California, again. Here’s the comparison
The COVID-19 pandemic elicited unprecedented government interventions into American life. Yet, the stringency and duration of government measures varied considerably across the U.S. …
Study
Freedom Wins
ABOUT THE AUTHORS Joel M. Zinberg, M.D., J.D. is the Director the Public Health and American Well-Being Initiative at Paragon Health Institute, and a senior…
Blog
Fauci Failure to Acknowledge Limited Vaccine Protection Undermines Faith in Government Advice
In a recent article Dr. Anthony Fauci acknowledged that, from the beginning of the pandemic, there was good reason to believe that vaccines against…
Regulatory Transparency Project
AUDIO: Explainer Episode 48 – The FDA & the Practice of Medicine: Possible Regulation of Off-Label Prescriptions
Senior Fellow Joel Zinberg joins the Regulatory Transparency Project to discuss possibly regulation of off-label prescriptions: On December 29, 2022, President Biden signed the Consolidated Appropriations…
Citation
FDA’s Medical Interference, Time for ESG Antitrust Action and other commentary
Libertarian: FDA’s Medical Interference The Wall Street Journal quoted Joel Zinberg on FDA banning practices: “Secreted within the 2023 omnibus appropriations…
Wall Street Journal
The FDA Wants to Interfere in the Practice of Medicine
Secreted within the 2023 omnibus appropriations bill—4,155 pages, spending $1.7 trillion—is a 19-line section that could change the way medicine is practiced. Physicians routinely prescribe…
